Volume 53, Issue 5, Pages (May 2008)

Slides:



Advertisements
Similar presentations
Volume 61, Issue 5, Pages (May 2012)
Advertisements

Volume 155, Issue 3, Pages (March 1996)
The PSA Era is not Over for Prostate Cancer
Volume 50, Issue 1, Pages (July 2006)
Volume 52, Issue 1, Pages (July 2007)
Volume 51, Issue 2, Pages (February 2007)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 44, Issue 6, Pages (December 2003)
Volume 4, Issue 5, Pages (September 2017)
Testosterone Therapy in Men With Prostate Cancer
Global Trends in Testicular Cancer Incidence and Mortality
Prostate Cancer: Highlights from 2006
Volume 49, Issue 2, Pages (February 2006)
Volume 66, Issue 3, Pages (September 2014)
Volume 51, Issue 4, Pages (April 2007)
Volume 65, Issue 5, Pages (May 2014)
Volume 199, Issue 4, Pages e131-e132 (April 2018)
Volume 60, Issue 6, Pages (December 2011)
Volume 181, Issue 4, Pages (April 2009)
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Prostate Cancer Epidemic in Sight?
Volume 52, Issue 4, Pages (October 2007)
Volume 72, Issue 5, Pages (November 2017)
Volume 62, Issue 6, Pages (December 2012)
Volume 63, Issue 4, Pages e53-e56 (April 2013)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 68, Issue 5, Pages (November 2015)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Volume 53, Issue 4, Pages (April 2008)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Prostate Cancer Detection: A View of the Future
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 68, Issue 3, Pages (September 2015)
Volume 67, Issue 3, Pages (March 2015)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 71, Issue 6, Pages (June 2017)
Laurent Boccon-Gibod  European Urology Supplements 
Volume 64, Issue 6, Pages (December 2013)
Volume 73, Issue 2, Pages (February 2018)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 58, Issue 1, Pages 1-7 (July 2010)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Optimising Hormone Therapy in Advanced Disease
Volume 71, Issue 5, Pages (May 2017)
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
European Urology Oncology
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
European Urology is “Your” Journal
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Axel Heidenreich  European Urology Supplements 
Volume 53, Issue 5, Pages (May 2008)
Volume 54, Issue 1, Pages (July 2008)
Volume 53, Issue 6, Pages (June 2008)
Volume 51, Issue 2, Pages (February 2007)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Axel Heidenreich  European Urology Supplements 
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 53, Issue 5, Pages 950-959 (May 2008) Secondary Therapy, Metastatic Progression, and Cancer-Specific Mortality in Men with Clinically High-Risk Prostate Cancer Treated with Radical Prostatectomy  Ofer Yossepowitch, Scott E. Eggener, Angel M. Serio, Brett S. Carver, Fernando J. Bianco, Peter T. Scardino, James A. Eastham  European Urology  Volume 53, Issue 5, Pages 950-959 (May 2008) DOI: 10.1016/j.eururo.2007.10.008 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 (A) Radiation therapy–free survival in high-risk prostate cancer patients treated with radical prostatectomy. (B) Hormonal therapy–free survival in high-risk prostate cancer patients treated with radical prostatectomy. European Urology 2008 53, 950-959DOI: (10.1016/j.eururo.2007.10.008) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 (A–B) Prostate cancer–specific mortality in high-risk and non–high-risk patients treated with radical prostatectomy. European Urology 2008 53, 950-959DOI: (10.1016/j.eururo.2007.10.008) Copyright © 2007 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.